Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at radiotherapy to prevent cancer spreading to the brain in patients with early stage small cell lung cancer (PCI01-EULINT 1)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
Small cell lung cancer (SCLC) is usually treated with chemotherapy. But sometimes the cancer can spread to other parts of the body, including the brain. Newly diagnosed patients with limited stage SCLC are often given a course of radiotherapy to the brain. This is to help stop cancer spreading there. This is called prophylactic (pronounced prof-ill-ack-tik) cranial irradiation (PCI).
Doctors were not sure what the best dose of radiotherapy was for PCI. The aim of this trial was to compare a standard dose to a higher dose, to see which was better in preventing lung cancer spread to the brain and to see if it helped people live longer.
Summary of results
The researchers found that a higher dose of radiotherapy was no better than standard dose radiotherapy in preventing cancer spread to the brain in people with SCLC.
This was a randomised trial. It recruited 720 people
- Half had standard dose radiotherapy to the brain
- Half had higher dose radiotherapy to the brain
The research team looked at some of their results 2 years after radiotherapy started. They found that
- There was no
statistically significantdifference in the number of people who developed cancer spread to the brain in the 2 treatment groups (29% with standard dose radiotherapy and 23% with the higher dose)
- Slightly more people were alive and cancer free (disease free survival) in the standard dose group (33%) compared to the higher dose group (29%)
- The number of people alive, with or without signs of cancer (overall survival]), was also higher in the standard dose group (42%) compared to the other group (37%)
It is not clear why the results for patients who had lower doses of radiotherapy were slightly better than those having higher doses.
Just over half of all patients had short term side effects, but they were generally mild and well tolerated. Slightly more people in the higher dose group had side effects than those in the standard dose group, but this could have been a chance result (in other words, it wasn’t
The research team concluded that patients with limited stage SCLC should continue to have the standard dose of radiotherapy to prevent cancer spreading to the brain.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Anna Greggor